# Attovia Therapeutics Inc. (ATTO)

Source: https://www.quantisnow.com/company/ATTO
Generated: 2026-11-09T20:43:31.347Z

- Ticker: ATTO
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2014
- SEC CIK: 0002058707
- Website: https://www.attovia.com/

## About

Attovia is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates have been internally discovered using its ATTOBODY biparatopic biologics platform. Attovia's ATTOBODY platform uses an evolution-driven, high-throughput process that allows for rapid discovery and creation of a high diversity of potential product candidates. Attovia's lead programs include ATTO-1310, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases; ATTO-2306, a long-acting bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases; and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin 47 in IND-enabling studies for inflammatory bowel disease. Attovia's other programs include highly innovative conditional 'AND' gated bispecific immune cell survival blockers and multispecifics.

## Latest ATTO news and filings

- 2026-11-05 21:05 UTC [Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic Dermatitis](https://www.quantisnow.com/insight/attovia-therapeutics-announces-positive-topline-12-week-results-from-phase-1b-6776026)
- 2026-10-27 20:05 UTC [Conference Announcement] [Attovia Therapeutics to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/attovia-therapeutics-to-participate-in-upcoming-investor-conferences-6759134)
- 2026-09-28 20:05 UTC [Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026](https://www.quantisnow.com/insight/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-6727649)
- 2026-09-03 20:05 UTC [Conference Announcement] [Attovia Therapeutics to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/attovia-therapeutics-to-participate-in-upcoming-investor-conferences-6704952)
- 2026-09-02 20:05 UTC [Public Offering] [Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update](https://www.quantisnow.com/insight/attovia-therapeutics-reports-second-quarter-2026-financial-results-and-provides-6703051)
- 2026-08-31 12:23 UTC [Analyst Coverage Initiated] [RBC Capital Mkts initiated coverage on Attovia Therapeutics with a new price target](https://www.quantisnow.com/insight/rbc-capital-mkts-initiated-coverage-on-attovia-therapeutics-with-a-6699225)
- 2026-08-31 12:23 UTC [Analyst Coverage Initiated] [Morgan Stanley initiated coverage on Attovia Therapeutics with a new price target](https://www.quantisnow.com/insight/morgan-stanley-initiated-coverage-on-attovia-therapeutics-with-a-new-6699224)
- 2026-08-31 12:22 UTC [Analyst Coverage Initiated] [Citigroup initiated coverage on Attovia Therapeutics with a new price target](https://www.quantisnow.com/insight/citigroup-initiated-coverage-on-attovia-therapeutics-with-a-new-price-6699222)
- 2026-08-31 12:22 UTC [Analyst Coverage Initiated] [Leerink Partners initiated coverage on Attovia Therapeutics with a new price target](https://www.quantisnow.com/insight/leerink-partners-initiated-coverage-on-attovia-therapeutics-with-a-new-6699221)
- 2026-08-06 20:05 UTC [Public Offering] [Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares](https://www.quantisnow.com/insight/attovia-therapeutics-announces-closing-of-upsized-initial-public-offering-and-6668733)
- 2026-08-06 09:57 UTC [Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq](https://www.quantisnow.com/insight/immune-mediated-disease-therapeutics-developer-attovia-therapeutics-debuts-on-nasdaq-6666733)
- 2026-08-05 00:50 UTC [Public Offering] [Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering](https://www.quantisnow.com/insight/attovia-therapeutics-announces-pricing-of-upsized-initial-public-offering-6663491)
- 2023-11-27 21:56 UTC [SEC Form 6-K] [SEC Form 6-K filed by Atento S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-atento-sa-5104715)
- 2023-10-20 20:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Atento S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-atento-sa-5030752)
- 2023-10-13 21:33 UTC [SEC Form 6-K] [SEC Form 6-K filed by Atento S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-atento-sa-5020363)
- 2023-10-03 20:41 UTC [SEC Form 6-K] [SEC Form 6-K filed by Atento S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-atento-sa-5001645)
- 2023-09-08 21:18 UTC [SEC Form 6-K] [SEC Form 6-K filed by Atento S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-atento-sa-4962341)
- 2023-08-31 20:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Atento S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-atento-sa-4947873)
- 2023-08-24 20:08 UTC [SEC Form 6-K] [SEC Form 6-K filed by Atento S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-atento-sa-4936896)
- 2023-08-07 15:13 UTC [SEC Form 25-NSE filed by Atento S.A.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-atento-sa-4854089)
- 2023-08-01 18:16 UTC [Conference Announcement] [Atento announces drawdown of $17 million in tranche 2 funding under its new interim financing](https://www.quantisnow.com/insight/atento-announces-drawdown-of-17-million-in-tranche-2-funding-4826945)
- 2023-08-01 13:03 UTC [SEC Form 6-K] [SEC Form 6-K filed by Atento S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-atento-sa-4824486)
- 2023-08-01 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Atento S.A.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-atento-sa-4822498)
- 2023-07-25 18:51 UTC [SEC Form POS AM filed by Atento S.A.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-atento-sa-4792533)
- 2023-07-24 21:20 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Atento S.A.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-atento-sa-4787846)
- 2023-07-24 21:19 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Atento S.A.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-atento-sa-4787842)
- 2023-07-24 21:18 UTC [SEC Form F-3/A filed by Atento S.A. (Amendment)](https://www.quantisnow.com/insight/sec-form-f-3a-filed-by-atento-sa-amendment-4787836)
- 2023-07-21 21:27 UTC [Atento Announces Delisting from NYSE; Delisting expected in Restructuring Plan](https://www.quantisnow.com/insight/atento-announces-delisting-from-nyse-delisting-expected-in-restructuring-plan-4782498)
- 2023-07-21 21:12 UTC [SEC Form 6-K] [SEC Form 6-K filed by Atento S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-atento-sa-4782411)
- 2023-07-21 20:25 UTC [Market Insight] [NYSE To Commence Delisting Proceedings Against Atento S.A.](https://www.quantisnow.com/insight/nyse-to-commence-delisting-proceedings-against-atento-sa-4782054)
- 2023-07-21 20:11 UTC [Market Insight] [Atento S.A. Shares Halted, News Pending](https://www.quantisnow.com/insight/atento-sa-shares-halted-news-pending-4781897)
- 2023-07-06 16:57 UTC [Market Chatter] [Shares of indsutrial stocks are trading lower amid overall market weakness on rate hike concerns. Further rate hikes could pressure economic activity and spending.](https://www.quantisnow.com/insight/shares-of-indsutrial-stocks-are-trading-lower-amid-overall-market-4726379)
- 2023-07-06 10:19 UTC [SEC Form 6-K] [SEC Form 6-K filed by Atento S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-atento-sa-4723952)
- 2023-07-06 10:10 UTC [SEC Form 6-K] [SEC Form 6-K filed by Atento S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-atento-sa-4723939)
- 2023-07-05 12:22 UTC [Market Insight] [Why Nocera Are Trading Higher By Around 89%; Here Are 20 Stocks Moving Premarket](https://www.quantisnow.com/insight/why-nocera-are-trading-higher-by-around-89-here-are-4717792)
- 2023-07-03 17:22 UTC [Market Insight] [Why Li Auto Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session](https://www.quantisnow.com/insight/why-li-auto-shares-are-trading-higher-by-around-7-4714310)
- 2023-07-03 16:15 UTC [Market Insight] [Nasdaq Edges Lower; ISM Manufacturing PMI Drops In June](https://www.quantisnow.com/insight/nasdaq-edges-lower-ism-manufacturing-pmi-drops-in-june-4713989)
- 2023-07-03 10:06 UTC [Atento enters into a restructuring support agreement with certain key financial stakeholders](https://www.quantisnow.com/insight/atento-enters-into-a-restructuring-support-agreement-with-certain-key-4712679)
- 2023-07-03 10:04 UTC [SEC Form 6-K] [SEC Form 6-K filed by Atento S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-atento-sa-4712675)
- 2023-06-24 00:11 UTC [SEC Form 6-K] [SEC Form 6-K filed by Atento S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-atento-sa-4681194)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ATTO
- Earnings history: https://www.quantisnow.com/earnings/ATTO
- Dividend history: https://www.quantisnow.com/dividends/ATTO
- Insider transactions: https://www.quantisnow.com/insiders/ATTO
- Options chain: https://www.quantisnow.com/options/ATTO
- SEC 8-K filings only: https://www.quantisnow.com/company/ATTO/8-k
- RSS and alerts for ATTO: https://www.quantisnow.com/docs/rss-feeds.md